Flagship Harbor Advisors, LLC Scynexis Inc Transaction History

Flagship Harbor Advisors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 16, 2024	SELL	$1.39 - $2.21 $7,644 - $12,155	-5,500 Reduced 30.99%	12,250 $18,000
Q4 2023 Jan 10, 2024	SELL	$1.56 - $2.24 $8,970 - $12,880	-5,750 Reduced 24.47%	17,750 $39,000
Q2 2023 Jul 11, 2023	BUY	$2.38 - $3.67 $5,950 - $9,175	2,500 Added 11.9%	23,500 $69,000
Q4 2022 Jan 13, 2023	BUY	$1.46 - $2.94 $6,570 - $13,230	4,500 Added 27.27%	21,000 $0
Q3 2022 Oct 13, 2022	SELL	$1.83 - $2.93 $18,300 - $29,300	-10,000 Reduced 37.74%	16,500 $40,000
Q2 2022 Jul 13, 2022	BUY	$1.77 - $3.87 $4,425 - $9,675	2,500 Added 10.42%	26,500 $49,000
Q1 2022 Apr 13, 2022	BUY	$3.56 - $6.66 $8,900 - $16,650	2,500 Added 11.63%	24,000 $94,000
Q4 2021 Feb 10, 2022	SELL	$4.94 - $7.69 $83,980 - $130,730	-17,000 Reduced 44.16%	21,500 $131,000
Q2 2021 Jul 26, 2021	BUY	$6.5 - $9.97 $250,250 - $383,845	38,500 New	38,500 $283,000

13.7M

21.9K

2.6K

Ticker SCYX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 32,651,800
Market Cap $40.5M
Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...

Get notified when there are updates to the investment portfolio of Flagship Harbor Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Flagship Harbor Advisors, LLC with notifications on news.